Icahn Sues Amylin For Docs On Rebuffed $3.5B Bristol Bid

Law360, Wilmington (April 12, 2012, 4:24 PM EDT) -- Activist investor Carl Icahn stepped up his pressure Thursday on Amylin Pharmaceuticals Inc. over the company's alleged rejection of a $3.5 billion offer from Bristol-Myers Squibb Co., filing suit to force the drugmaker to open its books and records to shareholders.

On Wednesday, Amylin “flatly refused” a so-called Section 220 demand to voluntarily turn over records related to Bristol Myers’ February offer — along with documents on a subsequent grant of stock options and a public offering allegedly priced well below that bid, Icahn Partners LP...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.